Linked Life Data

12643618

Source:http://linkedlifedata.com/resource/pubmed/id/12643618

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-3-19
pubmed:abstractText
Glucocorticosteroids (GCS) are established in the treatment of active Crohn's ileitis and ileocolitis. Recently, the topical steroid budesonide was found to be effective in untreated patients with Crohn's disease (CD) causing less side effects than conventional GCS. No clinical data have been reported about the effects of switching from conventional GCS to budesonide in terms of side effects and disease activity. The primary aim of this study was to evaluate the development of side effects after switching from conventional GCS treatment to Eudragit L-coated budesonide (pH-modified release formulation) in patients taking 5-30 mg prednisolone equivalent per day for at least two weeks. In all, 178 patients with active CD (N = 88) or CD in remission during GCS treatment (N = 90) were included. Conventional GCS treatment was tapered down during a maximum of three weeks, with simultaneous intake of 3 x 3 mg budesonide. Thereafter, patients received 3 x 3 mg budesonide alone for six weeks. GCS-related side effects, disease activity and adverse events were documented at study entry and after 0, 2, 4, and 6 weeks of budesonide treatment. The percentage of patients with GCS-related side effects decreased from 65.2% (intention-to-treat-population) at entry to 43.3% (P < 0.0001) at the end of the trial. The total number of GCS-related side effects decreased significantly from 269 to 90. Of the patients who entered the study with active disease under conventional GCS therapy, 38.6% were in remission at the end of the study. Of the patients who entered the study with CD in remission, 78% stayed in remission after switching from conventinal GCS to budesonide. In conclusion, switching from conventional GCS treatment to budesonide leads to a significant reduction of GCS related side effects in patients with CD without causing rapid deterioration of the disease.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
0163-2116
pubmed:author
pubmed:issnType
Print
pubmed:volume
48
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
373-8
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12643618-Administration, Oral, pubmed-meshheading:12643618-Adult, pubmed-meshheading:12643618-Budesonide, pubmed-meshheading:12643618-Crohn Disease, pubmed-meshheading:12643618-Delayed-Action Preparations, pubmed-meshheading:12643618-Dose-Response Relationship, Drug, pubmed-meshheading:12643618-Drug Administration Schedule, pubmed-meshheading:12643618-Female, pubmed-meshheading:12643618-Follow-Up Studies, pubmed-meshheading:12643618-Glucocorticoids, pubmed-meshheading:12643618-Humans, pubmed-meshheading:12643618-Hydrogen-Ion Concentration, pubmed-meshheading:12643618-Intestinal Mucosa, pubmed-meshheading:12643618-Male, pubmed-meshheading:12643618-Middle Aged, pubmed-meshheading:12643618-Probability, pubmed-meshheading:12643618-Prospective Studies, pubmed-meshheading:12643618-Risk Assessment, pubmed-meshheading:12643618-Severity of Illness Index, pubmed-meshheading:12643618-Statistics, Nonparametric, pubmed-meshheading:12643618-Treatment Outcome
pubmed:year
2003
pubmed:articleTitle
Replacement of conventional glucocorticoids by oral pH-modified release budesonide in active and inactive Crohn's disease: results of an open, prospective, multicenter trial.
pubmed:affiliation
Klinikum Stuttgart, Krankenhaus Bad Cannstatt, Stuttgart, Germany.
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Research Support, Non-U.S. Gov't, Multicenter Study